logo
  Join        Login             Stock Quote

Medwell Capital Reports 2012 Third Quarter Results

Monday, November 19, 2012 11:00 AM


EDMONTON, Nov. 19, 2012 /CNW/ - Medwell Capital Corp. ("Medwell" or the "Company") (TSX-V: MWC) today announced financial and operational results for the third quarter ended September 30, 2012.

Third Quarter Highlights

  • Completed a 20:1 share consolidation, for a total 4,550,446 shares outstanding at quarter end

  • Subsequent completion of a $4.3 million private placement and reorganization whereby Medwell's healthcare assets were transferred to a wholly owned limited partnership, and Messrs. Michael Salamon and Patrick Barry were appointed to the board of directors of Medwell Capital.

"It's been a very transformative period at Medwell," said Kevin Giese, President and CEO of Medwell. "The quarter saw the loss from continuing operations down significantly as a result of past reorganization efforts, and we recently injected new capital and restructured the Company to better position it to look for future investment opportunities."

Financial Results

The consolidated net loss from continuing operations of the Corporation in 2012 decreased significantly from prior year periods, largely as a result of a decrease in operating expenses that came about through the Corporations' past reorganization efforts:

  • For the three months ended September 30, 2012, the loss was $0.5 million ($0.10 per share), down significantly from a loss of $3.6 million ($0.79 per share) for the same period in 2011.  The results for the past quarter recognized a gain of $0.2 million on the fair value of the Corporation's investments, and included $0.2 million in extraordinary reorganization related costs. There was a substantial $3.4 million decrease in expenses from continuing operations in 2012 as compared to the same period in 2011.

  • For the nine months ended September 30, 2012, the loss was $3.1 million ($0.68 per share), after recognizing a loss of $1.0 million on the fair value of the Corporation's investments. The results represent a significant $10.1 million improvement over the prior year period's loss of $13.2 million ($2.90 per share), again largely as a result of a decrease in operating expenses.

The loss and comprehensive losses in 2012 also decreased significantly from the prior year periods: a loss of $1 million ($0.21 per share) for the three months ended September 30, 2012 as compared to $3.6 million ($0.79 per share) in the prior year period; and a loss of $3.8 million ($0.84 per share) for the nine months ended September 30, 2012 as compared to $13.2 million ($2.90 per share) in the prior year period. The 2012 results included a loss from discontinued operations of $0.5 million ($0.11 per share) and $0.7 million ($0.16 per share) for the three and nine month periods respectively.

At September 30, 2012, cash and cash equivalents and restricted cash totaled $4.1 million. The Corporation's working capital decreased $1.2 million from $3.9 million at year end to $2.7 million at September 30th, of which $0.6 million was used in continuing operations.  The Corporation subsequently raised $4.3 million from a private placement. The Corporation currently has sufficient working capital to meet its obligations as they come due.

At November 18, 2012, there were 7,270,071 common shares of the Corporation issued and outstanding.

For complete financial results, please see our filings at www.sedar.com.

About Medwell Capital Corp.

Medwell Capital Corp. is a Canadian-based investment and advisory firm. For further information please visit www.medwellcapital.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events.  These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.  Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

       
           
Medwell Capital Corp. 
Interim Condensed Consolidated Statements of Financial Position
(Unaudited)
           
(expressed in thousands of Canadian dollars)          
           
    September 30,
2012
$
  December 31,
2011
$
 
           
Assets          
           
Cash and cash equivalents   3,162   4,339  
Investments   6,925   7,875  
Restricted cash   917   2,210  
Accounts receivable   269   334  
Prepaid expenses   124   149  
Property and equipment   16   23  
           
    11,413   14,930  
           
Liabilities          
           
Accounts payable and accrued liabilities   500   424  
           
           
           
Guarantees          
           
Shareholders' Equity          
           
Share capital   162,144   162,144  
           
Contributed surplus   13,116   12,883  
           
Deficit   (164,347)   (160,521)  
           
    10,913   14,506  
           
    11,413   14,930  

         
         
Medwell Capital Corp. 
Interim Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
         
(expressed in thousands of Canadian dollars)        
         
  Nine-month period ended
September 30,
    Three-month period ended
September 30,
                 
  2012
$
  2011
$
    2012
$
  2011
$
                 
Revenue                
Contract services 913   1,302     163   420
                 
                 
Change in fair value of investments 970   6,401     (196)   2,178
Operating, general and administrative 2,820   7,665     820   1,780
Stock-based compensation 225   645     -   326
Depreciation of property and equipment 10   31     2   9
Loss on disposal of property and equipment -   3     -   -
Foreign exchange (gain) loss 31   (132)     -   (236)
Interest earned (31)   (134)     (13)   (28)
                 
  4,025   14,479     613   4,029
                 
Loss from continuing operations (3,112)   (13,177)     (450)   (3,609)
Loss from discontinued operations (714)   -     (518)   -
                 
Loss and comprehensive loss (3,826)   (13,177)     (968)   (3,609)
                 
Basic and diluted loss per common share -
  continuing operations (0.68)   (2.90)     (0.10)   (0.79)
                   
Basic and diluted loss per common share -
  discontinued operations   (0.16)   -     (0.11)   -
                   
Basic and diluted net loss per common share (0.84)   (2.90)     (0.21)   (0.79)
                   
Basic and diluted weighted average number
  of common shares outstanding 4,550   4,550     4,550   4,550

                 
                 
Medwell Capital Corp. 
Interim Condensed Consolidated Statements of Changes In Equity
(Unaudited)
                 
(expressed in thousands of Canadian dollars)                
                 
    Share
capital
$
  Contributed
surplus
$
 
Deficit
$
 
Total
$
Balance, December 31, 2011   162,144   12,883   (160,521)   14,506
                 
Net and comprehensive loss for
  the period   -   -   (3,826)   (3,826)
Employee share options:                
  Value of services recognized   -   233   -   233
                 
Balance, September 30, 2012   162,144   13,116   (164,347)   10,913
                 
                 
Balance, December 31, 2010   175,714   12,319   (148,664)   39,369
                 
Net and comprehensive loss for
  the period   -   -   (13,177)   (13,177)
Distribution of Spectral                
  Diagnostics Inc.   (13,750)   -   -   (13,570)
Employee share options:                
  Value of services recognized   -   645   -   319
                 
Balance, September 30, 2011   175,714   12,964   (158,232)   30,120

       
       

Medwell Capital Corp. 
Interim Condensed Consolidated Statements of Cash Flows
(Unaudited)
       
(expressed in thousands of Canadian dollars)      
    Nine-month period ended September 30,  
       
    2012
$
  2011
$
 
Cash provided by (used in)          
Operating activities          
Net loss from continuing operations   (3,112)   (13,177)  
(Gain) Loss on sale of investments   -   4,046  
Purchase of investments   (20)   (13,741)  
Proceeds from sale of investments   -   152   
Proceeds from (purchase of) short-term investments   -   (148)  
Purchase of property and equipment   -   (11)  
Transferred from restricted cash   1,193   532  
Items not involving cash          
  Unrealized loss on investments   970   2,335  
  Stock-based compensation   225   645  
  Depreciation of property and equipment   10   31  
  Loss on disposal of property and equipment   -   3  
  Unrealized foreign exchange gain   -   (77)  
    (734)   (19,390)  
Net change in non-cash working capital items   111   571  
    (623)   (18,819)  
Foreign exchange loss on cash and cash equivalents held in foreign
  currency   -   77  
           
Cash used in continuing operations   (623)   (18,742)  
Cash used in discontinued operations   (554)   (747)  
Decrease in cash and cash equivalents   (1,177)   (19,489)  
Cash and cash equivalents - Beginning of period   4,339   24,841  
           
Cash and cash equivalents - End of period   3,162   5,352  
Cash and cash equivalents consists of          
Bank accounts   1,339   3,176  
Interest bearing deposits and securities   1,823   2,176  
    3,162   5,352  
Supplemental cash flow information          
  Income taxes paid     $      -   $    -  
  Interest paid           -   -  
           
 

 

 

SOURCE: Medwell Capital Corp.

Tony Hesby
Medwell Capital Corp.
780-413-7152
780-408-3040 Fax
info@medwellcapital.com

Michael Moore
Investor Relations
TMX Equicom
619-467-7067
mmoore@tmxequicom.com

(Source: CNW )
(Source: Quotemedia)

Advertisement

Related Stories

  • No Stories Found

Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.